Diabetes drugs no fix for obesity

Doctors should not rush to prescribe a newer class of diabetes drug off-label for weight loss, an expert says, despite new research extolling the drugs’ potential virtues as slimming agents.

A meta-analysis published Wednesday provides some of the strongest confirmation yet that the glucagon-like peptide-1 receptor (GLP-1R) agonists exenatide and liraglutide can produce clinically significant weight loss, even in non-diabetics.

Reviewing 25 trials, researchers found the average weight loss after 20 weeks or more of treatment was 2.8 kg for